# Association between genotypes of *ABCB1*, *ABCG2* and *CYP3A5* and the risk of atrial fibrillation

Tzu-Yu Pan<sup>a</sup>, Tzu-Yen Lin<sup>b</sup>, Wei-Chung Tsai<sup>c,d\*</sup>, Ming-Tsang Wu<sup>a,b,e</sup>\*

<sup>a</sup>Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>b</sup>Department of Public Health, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>c</sup>Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

<sup>d</sup>Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan <sup>e</sup>Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

Running title: ABCB1, ABCG2, CYP3A5 and atrial fibrillation risk

### **Corresponding authors:**

Dr. Wei-Chung Tsai, MD, E-mail: <u>k920265@gap.kmu.edu.tw</u>

Dr. Ming-Tsang Wu, MD, ScD E-mail: e\_encourage@yahoo.com; 960021@cc.kmuh.org.tw

#### **ORCID:**

Tzu-Yu Pan, orcid.org/0000-0003-3005-1944

Tzu-Yen Lin, orcid.org/0009-0009-6310-2323

Wei-Chung Tsai, orcid.org/0000-0002-1123-6954

Ming-Tsang Wu, orcid.org/0000-0001-7307-7816

#### Abstract

1

8 9

14 15

2223

27

29 30

# 2 Background:

- 3 Atrial fibrillation (AF) is a prevalent clinical condition worldwide, with a high global incidence that
- 4 significantly impacts disease burden and mortality rates. Single nucleotide polymorphisms in
- 5 ABCB1, ABCG2 and CYP3A5 are common, but the clinical outcomes are poorly understood. This
- 6 study examines the association between the genetic variations of ABCB1, ABCG2 and CYP3A5 and
- 7 the risk of AF in a Taiwanese population.

#### **Methods:**

- 10 This case-control study recruited 216 AF patients from two hospitals in Taiwan between 2021 and
- 2023. Control groups were matched by age (± one year), gender, and AF-related variables from the
- 12 Taiwan Biobank. Logistic regression analyzed the association between three genetic variants and
- 13 AF risk.

#### **Results:**

- A significant association was noted between ABCG2 rs2231142 and AF risk. Those with ABCG2
- 17 rs2231142 G/T and T/T genotypes had a 1.91-fold (95% CI = 1.04-3.53) increased risk of AF
- compared to those with the G/G genotype. This association was particularly pronounced in males in
- those carrying ABCG2 rs2231143 T/T genotype having a 4.47-fold (95% CI = 1.02-19.67) increased
- 20 risk after adjusting for covariates. There were no overall significant associations between AF risk
- and the polymorphisms of ABCB1 rs4148738 and rs1128503, nor CYP3A5 rs776746.

#### **Conclusion:**

- A robust risk association between the ABCG2 rs2231142 T allele and AF in Asian populations,
- 25 particularly in male adults, suggests that genetic testing for this polymorphism could be integrated
- into risk assessment models for AF.
- **Keywords:** Single nucleotide polymorphisms, Atrial fibrillation, *ABCB1*, *ABCG2*, *CYP3A5*

# Nonstandard Abbreviations and Acronyms

31

1000Genomes	1000 Genomes Project				
AF	Atrial fibrillation				
ABCB1	Adenosine triphosphate binding cassette subfamily B member 1				
ABCG2	ATP-binding cassette subfamily G member 2				
ATPase	Adenosine triphosphatase				
BCRP	Breast cancer resistance protein				
CYP3A5	Cytochrome P450 family 3 subfamily A member 5				
CYP450	Cytochrome P450 proteins				
DOACs	Direct oral anticoagulants				
GBD 2017	Global Burden of Disease Study 2017				
gnomAD	Genome Aggregation Database				
GWAS	Genome-Wide Association Studies				
HbA1C	Glycated hemoglobin				
IRB	Institutional Review Board				
KMUH	Kaohsiung Medical University Hospital				
KMTTH	Kaohsiung Municipal Ta-Tung Hospital				
LDL	Low-density lipoprotein cholesterol				
MYOZ1	Myozenin 1				
P-gp	P-glycoprotein				
PITX2	Paired like homeodomain 2				
SNPs	Single Nucleotide Polymorphisms				
TG	Triglyceride				
TWB	Taiwan Biobank				
ZFHX3	Zinc finger homeobox 3				

# Introduction

Atrial fibrillation (AF) is recognized globally as a prevalent clinical condition that elevates the risk of systemic thromboembolism, heart failure, stroke, dementia and mortality, significantly impacting disease burden and mortality rates worldwide. <sup>1,2</sup> Current estimates indicate that approximately 33 million people are affected by AF globally, demonstrating its extensive reach and the urgency for comprehensive understanding and effective management strategies. <sup>3</sup> The prevalence of AF differs markedly between genders, with rates of 1.4% in males and 0.7% in females. Additionally, incidence rates are reported at 1.68 per 1000 males and 0.76 per 1000 females, highlighting a substantial gender disparity in AF occurrence. <sup>1,2</sup> Age also plays a crucial role, with the Global Burden of Disease Study 2017 (GBD 2017) revealing that AF prevalence increases with age—from 0.07% among those aged 30 to 34, to 8.18% for those aged 95 and above.

Reports have also suggested potential disparities in the incidence and characteristics of AF across different racial and ethnic groups. <sup>5-7</sup> In Taiwan, heart disease, primarily driven by AF, ranks as the leading cause of death in individuals aged 65 and above and the second leading cause of death overall, following cancer, according to the 2021 national mortality statistics from the Ministry of Health and Welfare. <sup>2</sup> Extensive research has been directed towards unraveling the mechanisms underlying AF. Predominantly, AF is seen as a consequence of diseases such as hypertension, ischemic and structural heart disease, which contribute to the electrical and structural remodeling of the atria. <sup>8-10</sup> Despite the known risk factors such as advancing age, heart disease, elevated blood pressure and excessive alcohol consumption, a significant number of cases occur without identifiable risk factors, hinting at a potential genetic predisposition to AF. This gap in understanding limits the development of effective treatments and highlights the necessity for further investigation, particularly in the realm of precision medicine. <sup>2,11</sup>

Over 60% of AF variability is attributed to genetic factors heightening AF susceptibility, influencing AF development and maintenance. <sup>12-14</sup> Genetic variations in the genes ABCB1 (adenosine triphosphate (ATP) binding cassette subfamily B member 1), ABCG2 (ATP-binding

cassette subfamily G member 2), and CYP3A5 (cytochrome P450 family 3 subfamily A member 5), responsible for encoding P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and cytochrome P450 proteins (CYP450) respectively, play a significant role in altering transporter function. These genetic variations impact crucial aspects of AF, including cardiac electrical conduction, ion channel function and structural remodeling. <sup>15,16</sup> Studies have found specific single nucleotide polymorphisms (SNPs) such as rs1128503 and rs4148738 in ABCB1, which modify P-gp expression; furthermore, ABCG2 rs2231142 G>T genotype has been linked to decreased BCRP protein expression, <sup>17,18</sup> while CYP3A5 is crucial in metabolizing anticoagulants and stroke-prevention drugs, and this process significantly impacts the achievement of appropriate anticoagulation levels in patients with AF. <sup>19</sup>

Understanding the relationship between these genetic variants and the risk of developing AF is essential as it can provide insight into underlying molecular mechanisms and potentially guide the development of targeted therapies in the era of precision medicine. <sup>20</sup> In recent years, precision medicine has garnered increasing attention, emphasizing the significant relationship between diseases and genes. <sup>21</sup> Each individual possesses a unique genome that can influence their disease susceptibility, treatment response and drug metabolism, <sup>22</sup> and through genetic testing and analysis, researchers can establish correlations between genetic variants and particular diseases. <sup>23</sup> This knowledge can predict an individual's disease risk, facilitate accurate disease diagnosis, and aid in selecting the most suitable treatment options; <sup>24</sup> however, the current understanding of the relationship between these gene variants and the risk of AF remains unclear. In this study, we aimed to investigate the association between genetic variants of *ABCB1* (rs1128503, rs4148738), ABCG2 (rs2231142) and CYP3A5 (rs776746), and the risk of AF.

#### Materials and methods

#### Study subjects

This is an ongoing case-control study. The case patients diagnosed as AF by board-certified cardiologists were recruited from Kaohsiung Medical University Hospital (KMUH) and Kaohsiung

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

Municipal Ta-Tung Hospital (KMTTH) between January 2021 and January 2023. The study subjects included individuals aged 20-85 years and willing to cooperate with blood-draw procedures. Patients undergoing cancer treatment, those with impaired renal function (eGFR<15 ml/min/1.73 m<sup>2</sup>) and those who could not cooperate were excluded from the study. After the written informed consent was received, a designated researcher administered a standardized and structured questionnaire and reviewed the medical charts to collect age, gender, history of hypertension and diabetes and blood test data such as glycated hemoglobin (HbA1C), serum creatinine, triglyceride (TG) and low-density lipoprotein cholesterol (LDL)). A total of 216 AF patients were enrolled in the study period. Potential healthy controls were selected from the Taiwan Biobank (TWB) cohort, a community-based cohort comprising healthy adults recruited from all over Taiwan. The TWB cohort, established in 2005, aimed to collect genetic and medical information from 200,000 ethnic Taiwanese individuals aged 20 years or above without a history of cancer, where this cohort underwent comprehensive data collection including questionnaires, physical examinations and biochemical tests on blood and urine samples, and has continued to collect biological samples to-date, including DNA, blood plasma and urine from study subjects, which can be provided to researchers in Taiwan for study purposes at a minimal cost. As of 2020, the TWB cohort had enrolled 122,068 potential study adults aged 30-75 years with baseline data. The Institutional Review Board (IRB) of KMUH approved this study. Among the 216 AF patients, 185 subjects have provided blood samples for genotyping results. In addition, in order to match the AF patients of similar age with healthy controls from TWB cohort, we further excluded 44 patients aged over 76 years and left 141 eligible cases in the study (Figure 1). Then, the case patients were matched with the controls (1: 1 ratio) based on age within a range of ±1 year and the same gender from TWB cohort with specific genotypes of ABCB1 (rs1128503, rs4148738), ABCG2 (rs2231142), and CYP3A5 (rs776746) (n = 108,829). The final study subjects were 141 AF cases and 141 healthy controls.

# Genotyping of ABCB1 (rs1128503, rs4148738), ABCG2 (rs2231142) and CYP3A5 (rs776746)

#### polymorphisms from the case study group

The QIAamp DNA Mini Kit (Qiagen, Germany) was used to extract genomic DNA from peripheral blood samples collected from patients in the case study group, following the manufacturer's instructions, while TaqMan probes designed explicitly for standardized SNPs assays (Thermo Fisher Scientific, Inc) were employed to assess single nucleotide polymorphic variations in the *ABCB1* (rs1128503, rs4148738), *ABCG2* (rs2231142) and *CYP3A5* (rs776746) genes. Probe IDs and SNPs regions are listed in **Table S1**.

For SNPs genotyping, a reaction mixture containing 10 µL was prepared, containing 10 ng of genomic DNA, 2X TaqMan® Master Mix, 20X Assay Working Stock probe and nuclease-free water. A negative control (no template) was included in the experiment. The cycling conditions adhered to the manufacturer's standard protocol as recommended where real-time PCR was conducted on all samples using the QuantStudio 3 instrument (Applied Biosystems) and QuantStudio™ Design & Analysis Software was employed to analyze the data and identify homozygous and heterozygous alleles. To ensure the reliability of the genotyping assays, approximately 9.4% of patients (n = 15/141) were randomly selected for the genotyping of each polymorphism; this additional step being performed to validate the consistency and accuracy of the genotyping results. The reaction of PCR for direct sequencing is shown in **Supplemental Material and Table S2** that was also performed to confirm the genotyping results (**Figure S1**). For TWB cohorts, we extracted the genotype information of *ABCB1* (rs1128503, rs4148738), *ABCG2* (rs2231142), and *CYP3A5* (rs776746) genes from Genome-Wide Genotyping: Affymetrix Axiom TWB and TWB 2.0 database, in which genotype analysis was either from the Axiom Genome-Wide TWB array or Axiom Genome-Wide TWB 2.0 array. <sup>25</sup>

#### Statistical analysis

The frequencies of ABCB1 (rs1128503), ABCG2 (rs2231142) and CYP3A5 (rs776746) genotypes were assessed for Hardy-Weinberg disequilibrium in the TWB-1 control group (n = 141).

A comparison of demographic characteristics and genotypes between the case group (n = 141) and the TWB-1 control group (n = 141) was performed. Logistic regression models were employed to investigate the impact of *ABCB1* (*rs1128503*, *rs4148738*), *ABCG2* (*rs2231142*), and *CYP3A5* (*rs776746*) genotypes on AF risk, both before and after adjusting for covariates, including age (continuous variables), gender, diabetes, hypertension, HbA1C, serum creatinine, TG and LDL. Odds ratios (OR), confidence intervals (CI) and p-values were calculated and presented. If both *ABCB1* (*rs1128503*, *rs4148738*), *ABCG2* (*rs2231142*) and *CYP3A5* (*rs776746*) genotypes showed significant differences between case patients and controls, the combined effect of both genes was further examined. These analyses were also stratified by gender. All statistical analyses were conducted using IBM SPSS Statistics 25 software.

#### Results

#### **Characteristics of the Study Population**

Table 1. Among these 141 AF patients, 48 (34.0%) were female and 93 (66.0%) were male, while the percentages of gender, age group (40-60 and > 60 years) and educational levels were identical in AF patients and TWB-1 controls. Additionally, between the two groups of AF patients and TWB-1 controls, the aforementioned variables (gender, age groups and other variables including diabetes, hypertension, HbA1c, serum creatinine, TG and LDL) were not significantly different (all p > 0.05). Of the 141 AF patients, 24.8% had diabetes and 35.5% had hypertension; additionally, the HbA1c level (6.2%) was higher than the normal range of 4.0-5.6%.

#### Allele frequencies in TWB cohort

The prevalence of *ABCB1 rs1128503 A/A*, *A/G*, and *G/G* was 41.8%, 46.8% and 11.3% respectively, for TWB-1 (n = 141). For *ABCB1 rs4148738 T/T*, *C/T*, and *C/C*, the prevalence was 34.0%, 41.8% and 24.1% respectively, for TWB-1. *ABCG2 rs2231142 G/G*, *G/T*, and *T/T* were 59.6%, 33.3% and 7.1% respectively, in TWB-1. *CYP3A5 rs776746 C/C*, *T/C*, and *T/T* were 46.1%,

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

risk.

44.0% and 9.9% respectively, in TWB-1 (**Table S3**). All frequencies of ABCB1 (rs1128503, rs4148738), ABCG2 (rs2231142), and CYP3A5 (rs776746) genotypes in TWB-1 were consistent with the statistics of the Hardy-Weinberg equilibrium, which were insignificant (p > 0.05) (**Table S3**). Association of ABCB1, ABCG2 and CYP3A5 polymorphisms **Table 2** shows the association of *ABCB1* (rs1128503, rs4148738), *ABCG2* (rs2231142), and CYP3A5 (rs776746) genotypes with AF risk before and after adjusting for other covariates (including diabetes, hypertension, HbA1c, serum creatinine, TG and LDL). Genotypes of ABCG2 rs2231142 G/T and T/T exhibited a significant risk of developing AF compared to G/G genotypes after adjusting for other covariates (AOR = 1.912, 95% CI = 1.035-3.53), although no significant difference was observed in the other three SNPs after adjustment. Categorized by sex, the significant effect of ABCG2 rs2231143 remained present in males but not females, likely due to the small sample size of female AF patients (n = 48) (Table 3). Males with the combined genotypes of ABCG2 rs2231143 G/T and T/T had a significant risk of AF when compared with males carrying ABCG2 rs2231143 G/G genotype (crude OR=2.005, 95% CI=1.118-3.596; AOR=2.179, 95% CI=0.894-5.307). There was also a trend toward statistical significance for the association between male subjects and AF (p = 0.021 and 0.041 before and after adjusting for other covariates), suggesting a potential risk factor associated with this haplotype in males. **Discussion** This hospital-based case-control study underscores the importance of the ABCG2 rs2231142 G/T and T/T genotypes, which exhibit a higher risk of developing AF than those with the G/G genotype, particularly among male patients. However, no associations were identified between the polymorphisms of ABCB1 rs4148738 and rs1128503, and CYP3A5 rs776746 genotypes and AF

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

ABCG2 belongs to a superfamily of 48 human ATP-binding cassette transporters, which typically facilitate the transport of various substrates and rely on ATP-binding for activation. The ABCG2 rs2231142 variant results in a substitution of glutamine with lysine (Q141K) in exon 5. Previous studies have reported that individuals carrying the ABCG2 rs2231142 variant (G/T and T/T) exhibit significantly lower levels of ABCG2 protein within red blood cells as well as reduced ABCG2 adenosine triphosphatase (ATPase) activity compared to those with the G/G genotype. The presence of the ABCG2 rs2231142 T allele leads to an approximately 50% reduction in ABCG2 protein expression. <sup>26</sup> Zhang et al. found that variations in the ABCG2 rs2231142 variant could impact the serum levels of pro-inflammatory and pro-angiogenic markers in chronic inflammatory arterial conditions, hinting at a correlation between inflammation and the ABCG2 rs2231142 variant. 27 These findings suggest that ABCG2 rs2231142 could play a crucial physiological role as an excreter of environmental and endogenous toxins, and it might influence the multidrug transporter function in human erythrocytes, corresponding to pharmacologically relevant genetic variations. <sup>28</sup> Furthermore, recent studies have emphasized that the pharmacogenetic implications of these findings could connote the efficacy of direct oral anticoagulants (DOACs) being enhanced, as genetic variants influence drug metabolism and response. 29,30 In recent years, DOACs such as apixaban, dabigatran, edoxaban and rivaroxaban have replaced vitamin K antagonists for treating AF due to their ease of use and better effectiveness. In a rat model of pharmacokinetic interaction, almonertinib significantly increased systemic exposure to apixaban and rivaroxaban by inhibiting ABCB1 and ABCG2. 31 Previous studies have shown variable results regarding the relationship between genotypes and DOACs in AF patients. Gulilat et al. reported that the ABCG2 rs2231142 T allele predicted higher concentrations of apixaban in Caucasian AF patients, <sup>32</sup> but was associated with a lower concentration and lower oral clearance of apixaban in Japanese AF patients. 33,34 Additionally, no correlations were observed between the ABCG2 rs2231142 and rivaroxaban concentrations in Japanese AF patients. 35 Nevertheless, we observed a significant increase in the risk of AF associated with the ABCG2 rs2231142 T allele in

patients treated with rivaroxaban (**Table S4**), indicating that this SNPs might affect the drug transporters and metabolism of DOACs, making additional studies necessary to clarify the role of this SNPs in DOACs pharmacokinetic interactions.

Previous studies have shown that the loss-of-function *ABCG2 rs2231142 T* allele is associated with hyperuricemia, which might contribute to vascular damage and cardiovascular diseases such as atrial fibrillation, coronary artery disease, heart failure and stroke. <sup>36-38</sup> Similar observations were noted in an earlier prospective cohort study conducted in Taiwan, where hyperuricemia emerged as an independent risk factor for mortality from all causes, total cardiovascular disease and ischemic stroke. <sup>39</sup> In other studies, it is also suggested that the effect size of the *ABCG2 rs2231142* is more significant in males. <sup>36,40,41</sup> Our current data showed a similar interaction, as we found a significant association between the *rs2231142 T* allele and AF risk in males, which was consistent with these Asian population studies, <sup>36-41</sup> and although previous studies have demonstrated that estrogen levels could affect *ABCG2* expression, <sup>42,43</sup> this might explain why we observed the association with atrial fibrillation risk predominantly in males rather than females.

Currently, no studies have examined the AF risk linked to the *ABCG2 rs2231142* genotype, but research on other SNPs regarding AF risk has been conducted. Genetic factors contributing to AF are gaining more attention, with estimates of heritability reaching 22% in the UK Biobank and 62% in a twin study conducted in Denmark. <sup>14,44</sup> Daniel et al. were the first to report the Genome-wide association studies (GWAS) for AF, where the upstream region of the transcription factor gene *PITX2* on 4q25 was significantly associated with AF. <sup>45</sup> Several other genetic loci related to AF have been identified, including variants in or near *ZFHX3* (*Zinc Finger Homeobox 3*), *PITX2* (*paired like homeodomain 2*), and *MYOZ1* (*myozenin 1*), which show the most associations. <sup>46</sup>

Our research further highlights the significant relationship between the *ABCG2 rs2231142 T* allele and increased AF risk, particularly in males. This suggests that integrating genetic testing for this polymorphism into risk assessment models for AF could enhance precision in AF management strategies, especially in populations with a high prevalence of this risk allele. Past studies have primarily focused on pharmacogenomics or the risk of cardiovascular and hyperuricemia. <sup>36-41</sup> The

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

association between polymorphisms of ABG2 rs2231142 genotypes and AF subjects might result from the influence of hyperuricemia, obesity, hypertension and dyslipidemia, as well as sex differences caused by estrogen levels, or both. <sup>47</sup> In the study conducted by Doshi et al., <sup>48</sup> ABCG2 expression was examined in male obesity mice. The findings indicated elevated levels of ABCG2 protein, suggesting a potential association between increased ABCG2 expression and obesity-related AF, although the mechanism of the influence of the ABCG2 rs2231142 locus on the risk effect of developing AF still needs to be investigated. **Table S5** shows the similar variant allele frequencies of ABCB1, ABCG2 and CYP3A5 genotypes in East Asians from different databases and from the datasets of TWB, suggesting the robustness of target genotype frequencies in the public-domain databases. The 1000 Genomes Project (1000Genomes) and the Genome Aggregation Database (gnomAD) are public websites that respectively encompass data from more than 2,500 individuals representing global populations and aggregate over 800,000 exome and whole-genome sequences from seven ethnic groups, sharing summary data with the scientific community (https://www.internationalgenome.org/ and https://reurl.cc/RWnZzg, accessed on 2024/4/18). The TWB is an ongoing prospective study that involves over 200,000 individuals aged 20-70 in Taiwan. The distributions of genotype and allelic frequencies in Taiwan and other populations such as American, European, African, South Asian, Central Asian and East Asian are summarized in Table **S6**. The distributions of allelic frequencies in other populations were taken from the database of NCBI (https://www.ncbi.nlm.nih.gov/, assessed on 2024/4/18). The ABCB1 rs1128503 G allele and rs4148738 T allele have a higher prevalence among Africans, with frequencies of 80% and 77% respectively, while the ABCG2 T allele is more common in American, East Asian and Taiwanese populations consistent with the findings reported by Alrajeh et al. <sup>49</sup> Their reports noted that the frequency of the allele associated with reduced ABCG2 function is exceptionally high among Asians while the frequency of the CYP3A5 C allele is lower in African populations, with a frequency of 31%; interestingly, the prevalence of the ABCG2 T allele is higher in East Asian, Taiwanese and American populations (29.8%, 31.5% and 22.5%, respectively) compared to

European, South Asian and African populations (9.8%, 9% and 2.6%, respectively). These differences may be attributed to factors such as database sources, study designs and ethnicities.

#### Conclusion

In conclusion, the findings suggest a strong association between the *ABCG2 rs2231142 T* allele and a higher risk of AF among Taiwanese male subjects, with a 4.5-fold higher risk compared to controls, and a 1.9-fold risk when combining *ABCG2* genotypes in the overall population. However, no significant associations were identified between the polymorphisms of *ABCB1 rs4148738* and *rs1128503*, as well as *CYP3A5 rs776746* genotypes and AF risk. Further studies with larger sample sizes are necessary to investigate the interaction of the *ABCG2 rs2231142* genotype with AF risk.

#### Acknowledgment

290 Not applicable.

289

291

298

302

310

311

314315

318

324

#### 292 Sources of Funding

- 293 This work was supported by grants from Kaohsiung Medical University Hospital
- 294 (KMUH108-8R71), Kaohsiung Medical University Research Center Grant (KMU-TC108A01),
- 295 from the Integrative Project of National Health Research Institutes and Kaohsiung Medical
- 296 University (NHRIKMU-111-I005), Ministry of Science and Technology (MOST
- 297 108-2638-B-037-001-MY2).

#### 299 Disclosures

- 300 The authors declare that they have no known competing financial interests or personal relationships
- that could have appeared to influence the work reported in this paper.

#### 303 Authors' contributions

- 304 Tzu-Yen Lin was responsible for Methodology, Validation, Investigation, Data curation; Tzu-Yu
- 305 Pan was responsible for Methodology, Validation, Formal analysis, Resources, Data curation,
- Writing original draft and Writing- Reviewing and Editing; Wei-Chung Tsai were responsible for
- Data Curation and Resources, Writing-Review and editing; Ming-Tsang Wu was responsible for
- 308 Conceptualization, Writing-Review and editing, Supervision, Project administration, Funding
- 309 acquisition.

#### Availability of data and materials

- 312 The data are not publicly available due to the nature of information that could compromise the
- 313 privacy of research participants.

#### Ethics approval and consent to participate

- 316 The study design was approved by the institutional review board of Kaohsiung Medical University
- 317 Hospital (KMUHIRB-G(I)-20200040).

#### 319 Supplemental Material

- 320 Supplemental Method
- 321 Tables S1–S6
- 322 Figure S1
- 323 References <sup>50</sup>

#### References

- 326 1. Chien K-L, Su T-C, Hsu H-C, Chang W-T, Chen P-C, Chen M-F, Lee Y-T. Atrial fibrillation
- prevalence, incidence and risk of stroke and all-cause death among Chinese. *International*
- *journal of cardiology*. 2010;139:173-180. doi: 10.1016/j.ijcard.2008.10.045
- 329 2. Andersen JH, Andreasen L, Olesen MS. Atrial fibrillation—a complex polygenetic disease.
- 330 European Journal of Human Genetics. 2021;29:1051-1060. doi:
- 331 10.1038/s41431-020-00784-8
- 332 3. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C,
- Lubitz SA, Magnani JW, Ellinor PT. 50 year trends in atrial fibrillation prevalence,
- incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. The
- 335 *Lancet*. 2015;386:154-162. doi: 10.1016/S0140-6736(14)61774-8
- 336 4. Melki S, Salem B, Soulimane A, Serhier Z, Dahdi S. Profile and evolution of the Global
- Burden of Morbidity in the Maghreb (Tunisia, Morocco, Algeria). The Triple burden of
- 338 morbidity. *La Tunisie Medicale*. 2018;96:760-773.
- 339 5. Zhang J, Johnsen SP, Guo Y, Lip GY. Epidemiology of atrial fibrillation:
- geographic/ecological risk factors, age, sex, genetics. Cardiac electrophysiology clinics.
- 341 2021;13:1-23. doi: 10.1016/j.ccep.2020.10.010
- 342 6. Nanda A, Kabra R. Racial differences in atrial fibrillation epidemiology, management, and
- outcomes. Current Treatment Options in Cardiovascular Medicine. 2019;21:1-11. doi:
- 344 10.1007/s11936-019-0793-5
- 7. Tamirisa KP, Al-Khatib SM, Mohanty S, Han JK, Natale A, Gupta D, Russo AM, Al-Ahmad
- A, Gillis AM, Thomas KL. Racial and ethnic differences in the management of atrial
- 347 fibrillation. *CJC open.* 2021;3:S137-S148. doi: 10.1016/j.cjco.2021.09.004
- 348 8. Čihák R, Haman L, Táborský M. 2016 ESC Guidelines for the management of atrial
- fibrillation developed in collaboration with EACTS. *Cor et vasa*. 2016;6:e636-e683. doi:
- 350 10.1093/eurhearti/ehw210
- 351 9. Gudbjartsson DF, Holm H, Sulem P, Masson G, Oddsson A, Magnusson OT,
- Saemundsdottir J, Helgadottir HT, Helgason H, Johannsdottir H. A frameshift deletion in the
- sarcomere gene MYL4 causes early-onset familial atrial fibrillation. *European heart journal*.
- 354 2016:ehw379. doi: 10.1093/eurheartj/ehw379
- 355 10. Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. *JACC*:
- 356 Clinical Electrophysiology. 2017;3:425-435. doi: 10.1016/j.jacep.2017.03.002
- 357 11. Baturina O, Chashkina M, Andreev D, Mirzaev K, Bykova A, Suvorov A, Yeryshova D,
- Suchkova S, Sychev D, Syrkin A. Pharmacokinetic and Pharmacogenetic Predictors of
- Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation
- Receiving Combined Antithrombotic Therapy. Journal of Personalized Medicine.
- 361 2023;13:1371. doi: 10.3390/jpm13091371
- 362 12. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF,
- Kim Y-H, McAnulty Jr JH, Zheng Z-J. Worldwide epidemiology of atrial fibrillation: a
- Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847. doi:

- 365 10.1161/CIRCULATIONAHA.113.005119
- Ishikawa K, Hajjar RJ. Current methods in cardiac gene therapy: overview. *Cardiac Gene Therapy: Methods and Protocols*. 2017:3-14. doi: 10.1007/978-1-4939-6588-5\_1
- 368 14. Christophersen IE, Ravn LS, Budtz-Joergensen E, Skytthe A, Haunsoe S, Svendsen JH,
- 369 Christensen K. Familial aggregation of atrial fibrillation: a study in Danish twins.
- 370 Circulation: Arrhythmia and Electrophysiology. 2009;2:378-383. doi:
- 371 10.1161/CIRCEP.108.786665
- 372 15. Lubitz SA, Lunetta KL, Lin H, Arking DE, Trompet S, Li G, Krijthe BP, Chasman DI,
- Barnard J, Kleber ME. Novel genetic markers associate with atrial fibrillation risk in
- Europeans and Japanese. Journal of the American College of Cardiology.
- 375 2014;63:1200-1210. doi: 10.1016/j.jacc.2013.12.015
- 376 16. Christophersen IE, Ellinor PT. Genetics of atrial fibrillation: from families to genomes.
- *Journal of human genetics.* 2016;61:61-70. doi: 10.1038/jhg.2015.44
- 378 17. Gong IY, Mansell SE, Kim RB. Absence of both MDR 1 (ABCB 1) and Breast Cancer
- Resistance Protein (ABCG 2) Transporters Significantly Alters Rivaroxaban Disposition and
- Central Nervous System Entry. Basic & clinical pharmacology & toxicology.
- 381 2013;112:164-170. doi: 10.1111/bcpt.12005
- 382 18. Mizuno T, Fukudo M, Fukuda T, Terada T, Dong M, Kamba T, Yamasaki T, Ogawa O,
- Katsura T, Inui K-i. The effect of ABCG2 genotype on the population pharmacokinetics of
- sunitinib in patients with renal cell carcinoma. Therapeutic drug monitoring.
- 385 2014;36:310-316. doi: 10.1097/FTD.0000000000000025
- 386 19. Sychev DA, Sokolov AV, Reshetko OV, Fisenko VP, Sychev IN, Grishina EA, Bochkov PO,
- 387 Shevchenko RV, Abdullaev SP, Denisenko NP. Influence of ABCB1, CYP3A5 and CYP3A4
- gene polymorphisms on prothrombin time and the residual equilibrium concentration of
- rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice.
- 390 Pharmacogenetics and Genomics. 2022;32:301-307. doi: 10.1097/FPC.0000000000000483
- 391 20. Sinner MF, Ellinor PT, Meitinger T, Benjamin EJ, Kääb S. Genome-wide association studies
- of atrial fibrillation: past, present, and future. *Cardiovascular research*. 2011;89:701-709.
- 393 doi: 10.1093/cvr/cvr001
- 394 21. König IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine?
- 395 European respiratory journal. 2017;50. doi: 10.1183/13993003.00391-2017
- 396 22. Ramaswami R, Bayer R, Galea S. Precision medicine from a public health perspective.
- 397 Annual Review of Public Health. 2018;39:153-168. doi:
- 398 10.1146/annurev-publhealth-040617-014158
- 399 23. Robinson PN. Deep phenotyping for precision medicine. *Human mutation*. 2012;33:777-780.
- doi: 10.1002/humu.22080
- 401 24. McGrath S, Ghersi D. Building towards precision medicine: empowering medical
- professionals for the next revolution. BMC medical genomics. 2016;9:1-6. doi:
- 403 10.1186/s12920-016-0183-8
- 404 25. Feng Y-CA, Chen C-Y, Chen T-T, Kuo P-H, Hsu Y-H, Yang H-I, Chen WJ, Su M-W, Chu

- H-W, Shen C-Y. Taiwan Biobank: A rich biomedical research database of the Taiwanese population. *Cell Genomics*. 2022;2. doi: 10.1016/j.xgen.2022.100197
- Dong Z, Guo S, Yang Y, Wu J, Guan M, Zou H, Jin L, Wang J. Association between ABCG 2 Q141K polymorphism and gout risk affected by ethnicity and gender: a systematic review and meta-analysis. *International journal of rheumatic diseases*. 2015;18:382-391. doi:
- 410 10.1111/1756-185X.12519
- 27. Zhang D, Ding Y, Wang X, Xin W, Du W, Chen W, Zhang X, Li P. Effects of ABCG2 and
- SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and
- diabetes mellitus treated with rosuvastatin. European journal of clinical pharmacology.
- 414 2020;76:939-946. doi: 10.1007/s00228-020-02882-4
- 415 28. Cleophas M, Joosten L, Stamp LK, Dalbeth N, Woodward OM, Merriman TR. ABCG2
- polymorphisms in gout: insights into disease susceptibility and treatment approaches.
- 417 Pharmacogenomics and personalized medicine. 2017:129-142. doi:
- 418 10.2147/PGPM.S105854
- 419 29. Kim H, Song T-J, Yee J, Kim D-H, Park J, Gwak HS. ABCG2 gene polymorphisms may
- affect the bleeding risk in patients on apixaban and rivaroxaban. Drug Design, Development
- 421 and Therapy. 2023:2513-2522. doi: 10.2147/DDDT.S417096
- 422 30. Nakagawa J, Kinjo T, Aiuchi N, Ueno K, Tomita H, Niioka T. Impacts of pregnane X
- receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough
- 424 concentrations of apixaban in patients with non-valvular atrial fibrillation. European Journal
- *of Clinical Pharmacology*. 2023;79:127-135. doi: 10.1007/s00228-022-03424-w
- 426 31. Wang Z, Li Y, He X, Fu Y, Li Y, Zhou X, Dong Z. In vivo evaluation of the pharmacokinetic
- interactions between almonertinib and rivaroxaban, almonertinib and apixaban. Frontiers in
- 428 *Pharmacology*. 2023;14:1263975. doi: 10.3389/fphar.2023.1263975
- 429 32. Gulilat M, Keller D, Linton B, Pananos AD, Lizotte D, Dresser GK, Alfonsi J, Tirona RG,
- Kim RB, Schwarz UI. Drug interactions and pharmacogenetic factors contribute to variation
- in apixaban concentration in atrial fibrillation patients in routine care. *Journal of Thrombosis*
- 432 and Thrombolysis. 2020;49:294-303. doi: 10.1007/s11239-019-01962-2
- 433 33. Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, Tabuchi Y, Ozawa T, Itoh H,
- Ohno S. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult
- patients with atrial fibrillation. British journal of clinical pharmacology. 2018;84:1301-1312.
- doi: 10.1111/bcp.13561
- 437 34. Ueshima S, Hira D, Fujii R, Kimura Y, Tomitsuka C, Yamane T, Tabuchi Y, Ozawa T, Itoh H,
- Horie M. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough
- concentrations of apixaban in Japanese patients with atrial fibrillation. *Pharmacogenetics*
- 440 and genomics. 2017;27:329-336. doi: 10.1097/FPC.000000000000294
- 441 35. Nakagawa J, Kinjo T, Iizuka M, Ueno K, Tomita H, Niioka T. Impact of gene
- polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of
- rivaroxaban in patients with atrial fibrillation. Basic & Clinical Pharmacology & Toxicology.
- 444 2021;128:297-304. doi: 10.1111/bcpt.13488

- 445 36. Cheng S-T, Wu S, Su C-W, Teng M-S, Hsu L-A, Ko Y-L. Association of ABCG2
- 446 rs2231142-A allele and serum uric acid levels in male and obese individuals in a Han
- Taiwanese population. *Journal of the Formosan Medical Association*. 2017;116:18-23. doi:
- 448 10.1016/j.jfma.2015.12.002
- 449 37. Kanbay M, Segal M, Afsar B, Kang D-H, Rodriguez-Iturbe B, Johnson RJ. The role of uric
- acid in the pathogenesis of human cardiovascular disease. *Heart*. 2013;99:759-766. doi:
- 451 10.1136/heartjnl-2012-302535
- 452 38. Liu J, Yang W, Li Y, Wei Z, Dan X. ABCG2 rs2231142 variant in hyperuricemia is modified
- by SLC2A9 and SLC22A12 polymorphisms and cardiovascular risk factors in an elderly
- 454 community-dwelling population. BMC Medical Genetics. 2020;21:1-9. doi:
- 455 10.1186/s12881-020-0987-4
- 456 39. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent
- risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort
- 458 study. Arthritis Care & Research. 2009;61:225-232. doi: 10.1002/art.24164
- 459 40. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E,
- Wallace C, Farrall M. Meta-analysis of 28,141 individuals identifies common variants
- within five new loci that influence uric acid concentrations. *PLoS genetics*.
- 462 2009;5:e1000504. doi: 10.1371/journal.pgen.1000504
- 463 41. Fu S, Luo L, Ye P, Xiao W. Epidemiological associations between hyperuricemia and
- 464 cardiometabolic risk factors: a comprehensive study from Chinese community. BMC
- 465 *cardiovascular disorders*. 2015;15:1-5. doi: 10.1186/s12872-015-0116-z
- 466 42. Ee PLR, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. Identification of a novel
- estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer
- 468 research. 2004;64:1247-1251. doi: 10.1158/0008-5472.can-03-3583
- 469 43. Chang F-W, Fan H-C, Liu J-M, Fan T-P, Jing J, Yang C-L, Hsu R-J. Estrogen enhances the
- expression of the multidrug transporter gene ABCG2—increasing drug resistance of breast
- cancer cells through estrogen receptors. *International Journal of Molecular Sciences*.
- 472 2017;18:163. doi: 10.3390/ijms18010163
- 473 44. Weng L-C, Choi SH, Klarin D, Smith JG, Loh P-R, Chaffin M, Roselli C, Hulme OL,
- Lunetta KL, Dupuis J. Heritability of atrial fibrillation. Circulation: Cardiovascular
- 475 Genetics. 2017;10:e001838. doi: 10.1161/CIRCGENETICS.117.001838
- 476 45. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A,
- Jonasdottir A, Baker A, Thorleifsson G, Kristjansson K. Variants conferring risk of atrial
- fibrillation on chromosome 4q25. *Nature*. 2007;448:353-357. doi: 10.1038/nature06007
- 479 46. Tucker NR, Clauss S, Ellinor PT. Common variation in atrial fibrillation: navigating the path
- from genetic association to mechanism. *Cardiovascular research*. 2016;109:493-501. doi:
- 481 10.1093/cvr/cvv283
- 482 47. Maharani N, Ting YK, Cheng J, Hasegawa A, Kurata Y, Li P, Nakayama Y, Ninomiya H,
- 483 Ikeda N, Morikawa K. Molecular mechanisms underlying urate-induced enhancement of
- 484 Kv1. 5 channel expression in HL-1 atrial myocytes. Circulation Journal.

- 485 2015;79:2659-2668. doi: 10.1253/circj.CJ-15-0416
- 48. Doshi M, Takiue Y, Saito H, Hosoyamada M. The increased protein level of URAT1 was
   487 observed in obesity/metabolic syndrome model mice. *Nucleosides, Nucleotides and Nucleic* 488 *Acids*. 2011;30:1290-1294. doi: 10.1080/15257770.2011.603711
- 489 49. Alrajeh K, Roman YM. The frequency of rs2231142 in ABCG2 among Asian subgroups:
   490 implications for personalized rosuvastatin dosing. *Pharmacogenomics*. 2023;24:15-26. doi: 10.2217/pgs-2022-0155
- 492 50. Abdrakhmanov A, Akilzhanova A, Shaimerdinova A, Zhalbinova M, Tuyakova G, Abildinova S, Albayev R, Ainabekova B, Chinybayeva A, Suleimen Z. The distribution of the genotypes of ABCB1 and CES1 polymorphisms in Kazakhstani patients with atrial fibrillation treated with DOAC. *Genes*. 2023;14:1192.

Figure Legends

Figure 1. Flow chart comparing the genetic risk of AF in our study patients and Taiwan biobank's healthy subjects.

**Table 1.** Demographic characteristics of atrial fibrillation and their comparison groups

504

505

D 11 1 4 14	Number (%)				
Demographic characteristics	Cases (N=141)	TWB-1 (N=141)			
Gender					
Male	93 (66.0)	93 (66.0)			
Female	48 (34.0)	48 (34.0)			
Age (years)		•			
< 40	1 (0.71)	1(0.71)			
40–60	26 (18.44)	26 (18.44)			
> 60	114 (80.45)	114 (80.45)			
$Mean \pm SD$	66.3±7.8	$66.3 \pm 7.8$			
Median	68.0	68.0			
IQR	63.0-72.0	63.0 - 72.0			
Diabetes					
No	106 (75.2)	116 (82.3)			
Yes	35 (24.8)	25 (17.7)			
Hypertension	,	- ( ,			
No	91 (64.5)	100 (71.0)			
Yes	50 (35.5)	41 (29.0)			
HbA1c (%)					
$Mean \pm SD$	6.2±1.1	$6.2 \pm 1.1$			
Median	6.0	5.8			
IQR	5.6-6.6	5.5-6.3			
Serum creatinine (mg/dl)					
Mean ± SD	$1.2 \pm 0.7$	$0.8 \pm 0.3$			
Median	1.1	0.8			
IQR	0.8-1.3	0.6-0.9			
TG (mg/dl)					
Mean ± SD	$102.6 \pm 53.7$	$116.5 \pm 68.8$			
Median	90.0	99.0			
IQR	66.0-126.0	70.0-134.0			
LDL (mg/dl)					
Mean ± SD	$78.5 \pm 30.8$	$114.6 \pm 28.8$			
Median	73.9	113.0			
IQR	55.8-95.8	95-134			

**Abbreviations:** TWB, Taiwan Biobank; SD, standard deviation; IQR, interquartile range; HbA1c, glycated hemoglobin; TG, triglycerides; LDL, low-density lipoprotein cholesterol.

**Table 2.** Distribution of *ABCB1*, *ABCG2*, and *CYP3A5* genotypes and odds ratios among atrial fibrillation cases and Taiwan biobank controls

Genes/SNPs	Genotypes _	Cases (N=141)		TWB-1 <sup>a</sup> (N=141)		Crude OR	$\mathbf{AOR}^{b}$
		N	(%)	N	(%)	(95% CI)	(95% CI)
	AA	65	46.1	59	41.8	1	1
	AG	63	44.7	66	46.8	0.866 (0.529-1.419)	1.001 (0.531-1.888)
ABCB1-rs1128503	GG	13	9.2	16	11.4	0.738 (0.327-1.662)	0.465 (0.168-1.285)
ADCD1-181120303	p-trend					0.414	0.271
	AA+AG	128	90.8	125	88.7	1	1
	GG	13	9.2	16	11.3	0.793 (0.367-1.717)	0.465 (0.177-1.224)
	TT	48	34.0	48	34.0	1	1
	CT	60	42.6	59	41.8	1.107 (0.594-1.741)	1.190 (0.603-2.349)
ABCB1-rs4148738	CC	33	23.4	34	24.2	0.971 (0.520-1.812)	0.831 (0.369-1.873)
ADCD1-184140730	p-trend					0.937	0.741
	TT+CT	108	76.6	107	75.9	1	1
	CC	33	23.4	34	24.1	0.962 (0.556-1.664)	0.753 (0.368-1.541)
	GG	63	44.7	84	59.6	1	1
	GT	64	45.3	47	33.3	1.816 (1.103-2.989)	1.880 (0.992-3.560)
ABCG2-rs2231142	TT	14	10.0	10	7.1	1.867 (0.778-4.477)	1.791 (0.599-5.356)
	p-trend					0.022	0.072
	GG	63	44.7	84	59.6	1	1
	GT+TT	78	55.3	57	40.4	1.825 (1.137-2.927)	1.912(1.035-3.530)
CYP3A5-rs776746	CC	63	44.7	65	46.1	1	1
	TC	63	44.7	62	44.0	1.048 (0.640-1.716)	0.879 (0.468-1.652)
	TT	15	10.6	14	9.9	1.105 (0.493-2.476)	1.941 (0.675-5.578)
	p-trend					0.786	0.502
	CC+TC	126	89.4	127	90.1	1	1
	TT	15	10.6	14	9.9	1.080 (0.501-2.330)	2.058 (0.293-2.085)

**Abbreviations:** *ABCB1*, ATP binding cassette subfamily B member 1; *ABCG2*, ATP binding cassette subfamily G member 2; AOR, adjusted odds ratio; *CYP3A5*, cytochrome P450 3A5; TWB, Taiwan Biobank (https://taiwanview.twbiobank.org.tw/search).

<sup>&</sup>lt;sup>a</sup> TWB-1 using 1:1 individual matching of age (+/- 1 year) and genders from original 108,829 subjects.

<sup>&</sup>lt;sup>b</sup> Adjusting by diabetes, hypertension, glycated hemoglobin (HbA1c), serum creatinine, triglycerides (TG) and low-density lipoprotein cholesterol (LDL).

**Table 3.** Logistic regression analysis with risk estimates of *ABCB1*, *ABCG2*, and *CYP3A5* 

genotypes in Taiwanese female and male atrial fibrillation patients

516


genotypes in Taiwane				
Genes/SNPs (N, %)	Cases (N=141)	TWB-1 <sup>a</sup> (N=141)	Crude OR (95%CI)	AOR <sup>o</sup> (95%CI)
Female (N=48)	(11-171)	(11-1-1)	(75 /001)	
ABCB1- rs1128503				
AA	26 (54.2)	19 (39.6)	1	1
AG	,	, , ,	0.635	0.780 (0.266-2.284)
110	20 (41.7)	23 (47.9)	(0.274-1.475)	0.700 (0.200 2.201)
GG	0 (4 0)	c (10.5)	0.244	0.106 (0.015-0.724)
	2 (4.2)	6 (12.5)	(0.044-1.342)	,
p-trend			0.138	0.047
AA+AG	46 (95.8)	42 (87.5)	1	1
GG	2 (4.2)	6 (12.5)	0.304	0.118 (0.018-0.761)
	2 (4.2)	0 (12.3)	(0.058-1.591)	
ABCB1- rs4148738				
TT	15 (31.3)	17 (35.4)	1	1
CT	17 (35.4)	20 (41.7)	0.963	1.516 (0.487-4.721)
	17 (33.4)	20 (41.7)	(0.373-2.488)	
CC	16 (33.3)	11 (22.9)	1.648	1.757 (0.522-5.918)
	10 (33.3)	11 (22.))	(0.586-4.641)	0.040
p-trend	20 (66 7)	05 (55.4)	0.907	0.349
TT+CT	32 (66.7)	37 (77.1)	1 602(0 602 4 144)	1 420 (0 400 4 101)
CC	16 (33.3)	11 (22.9)	1.682(0.683-4.144)	1.432 (0.489-4.191)
ABCG2-				
rs2231142	26 (54.1)	21 (64.6)	1	1
GG GT	26 (54.1)	31 (64.6)	1.788	2.080 (0.771-5.611)
GI	21 (43.8)	14 (29.2)	(0.762-4.200)	2.060 (0.771-3.011)
TT			0.702-4.200)	0.143 (0.005-3.803)
11	1 (2.1)	3 (6.2)	(0.039-4.054)	0.143 (0.003-3.803)
p-trend			0.609	0.682
GG	26 (54.1)	31 (64.6)	1	1
GT+TT	22 (45.9)	17 (35.4)	1.543(0.680-3.503)	1.692 (0.631-4.535)
CYP3A5- rs776746	22 (1819)	17 (8811)	1.0 15 (0.000 5.005)	1.052 (0.051 1.055)
CC	23 (47.9)	21 (43.8)	1	1
CT	,	, , ,	0.706	0.714 (0.261-1.951)
	17 (35.4)	22 (45.8)	(0.297-1.678)	
TT	0 (167)	5 (10 A)	1.461	2.303 (0.555-9.599)
	8 (16.7)	5 (10.4)	(0.413-5.172)	,
p-trend			0.757	0.492
CC+CT	40 (83.3)	43 (89.6)	1	1
TT	8 (16.7)	5 (10.4)	1.720(0.519-5.696)	2.767
	6 (10.7)	J (10.4)		(0.710-10.784)
Male (N=93)				
ABCB1- rs1128503	20 (44.5)	40 (40 0)	4	4
AA	39 (41.9)	40 (43.0)	1	1 225 (0 400 2 415)
AG	43 (46.3)	43 (46.2)	1.026	1.235 (0.490-3.115)
CC	( /	( -· )	(0.557-1.889)	0.007 (0.015.2.905)
GG	11 (11.8)	10 (10.8)	1.128	0.907 (0.215-3.825)
n tuand	` ,	` '	(0.431-2.956)	0.022
<b>p-trend</b> AA+AG	82 (88 2)	83 (89.2)	0.901	0.922
GG	82 (88.2) 11 (11.8)	10 (10.8)	1.113 (0.449-2.764)	0.792 (0.203-3.100)
ABCB1- rs4148738	11 (11.0)	10 (10.6)	1.113 (0.447-2.704)	0.174 (0.405-5.100)
TT	33 (35.5)	31 (33.3)	1	1
CT	, , ,	, , ,	1.036	0.892 (0.333-2.387)
~ -	43 (46.2)	39 (42.0)	(0.538-1.993)	(0.000 2.007)
CC	17 (10 2)	22 (24 7)	0.694	0.274 (0.071-1.053)
	17 (18.3)	23 (24.7)	(0.313-1.539)	, ,
		22	,	

p-trend			0.577	0.089
TT+CT	76 (81.7)	70 (75.3)	1	1
CC	17 (18.3)	23 (24.7)	0.681 (0.336-1.379)	0.317 (0.096-1.048)
ABCG2-				
rs2231142				
GG	37 (39.8)	53 (57.0)	1	1
GT	12 (16.2)	22 (25 5)	1.867	1.718 (0.667-4.425)
	43 (46.2)	33 (35.5)	(1.006-3.463)	
TT	12 (14 0)	7 (7.5)	2.660	4.474
	13 (14.0)	7 (7.5)	(0.969-7.306)	(1.018-19.671)
p-trend			0.021	0.041
GG	37 (39.8)	53 (57.0)	1	1
GT+TT	56 (60.2)	86 (43.0)	2.005 (1.118-3.596)	2.179 (0.894-5.307)
CYP3A5- rs776746	,	•	· · · · · · · · · · · · · · · · · · ·	,
CC	40 (43.0)	44 (47.3)	1	1
CT	46 (49.5)	40 (43.0)	1.265 (0.693-2.311)	0.756 (0.301-1.896)
TT	7 (7.5)	9 (9.7)	0.856 (0.292-2.511)	0.885 (0.139-5.621)
p-trend	` /	` ,	0.806	0.646
CC+CT	86 (92.5)	84(90.3)	1	1
TT	7 (7.5)	9 (9.7)	0.760 (0.271-2.133)	1.087 (0.187-6.326)

**Abbreviations:** *ABCB1*, ATP binding cassette subfamily B member 1; *ABCG2*, ATP binding cassette subfamily G member 2; AOR, adjusted odds ratio; *CYP3A5*, cytochrome P450 3A5; TWB, Taiwan Biobank (https://taiwanview.twbiobank.org.tw/search).

<sup>&</sup>lt;sup>a</sup> TWB-1 using 1:1 individual matching of age (+/- 1 year) and genders from original 108,829 subjects.

<sup>&</sup>lt;sup>b</sup> Adjusting by diabetes, hypertension, glycated hemoglobin (HbA1c), serum creatinine, triglycerides (TG) and low-density lipoprotein cholesterol (LDL).



**Figure 1.** Flow chart comparing the genetic risk of AF in our study patients and Taiwan biobank's healthy subjects.